Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

A genetic screen identifies genes essential for development of myelinated axons in zebrafish.
Less Frequent and Less Severe Flu-Like Syndrome in Interferon Beta-1a Treated Multiple Sclerosis Patients with at Least One Allele Bearing the G>C Polymorphism at Position -174 of the IL-6 Promoter Gene.
Inhibition of RNA polymerase I as a therapeutic strategy to promote cancer-specific activation of p53.
Cladribine interferes with IL-1β synaptic effects in experimental multiple sclerosis.
Safety and efficacy of mitoxantrone in pediatric patients with aggressive multiple sclerosis.
Safety Study of Interferon Beta-1a for Acute Stroke
Effect of IFN β-1b on CXCR4-dependent chemotaxis in T cells from multiple sclerosis patients.
TGFβ Signaling Regulates the Timing of CNS Myelination by Modulating Oligodendrocyte Progenitor Cell Cycle Exit through SMAD3/4/FoxO1/Sp1.
[Results of a comparative clinical trial of the Russian Β - interferon-1b bioanalogue (infibeta)].
Treatment Optimization in MS: Canadian MS Working Group Updated Recommendations.
Development of experimental autoimmune encephalomyelitis (EAE) in mice requires vitamin D and the vitamin D receptor.
Impact of cladribine on soluble adhesion molecules in multiple sclerosis.
Patterns of Treatment Switching in Multiple Sclerosis Therapies in US Patients Active on Social Media: Application of Social Media Content Analysis to Health Outcomes Research.
The scales and tales of myelination: using zebrafish and mouse to study myelinating glia.
The brain antigen-specific B cell response correlates with glatiramer acetate responsiveness in relapsing-remitting multiple sclerosis patients.
Receptos doses first patient in Phase 2/3 trial for RPC1063 in multiple sclerosis
Temporal relationship between elevation of epstein-barr virus antibody titers and initial onset of neurological symptoms in multiple sclerosis.
Revimmune (High-Dose Cyclophosphamide) for Autoimmune Diseases
First-in-class thyrotropin-releasing hormone (TRH)-based compound binds to a pharmacologically distinct TRH receptor subtype in human brain and is effective in neurodegenerative models.
Rituximab versus fingolimod after natalizumab in multiple sclerosis patients.
Therapeutic vaccine for acute and chronic motor neuron diseases: implications for amyotrophic lateral sclerosis.
Dose titration of BAF312 attenuates the initial heart rate reducing effect in healthy subjects.
Clinically feasible MTR is sensitive to cortical demyelination in MS.
GNbAC1, a humanized monoclonal antibody against the envelope protein of multiple sclerosis-associated endogenous retrovirus: a first-in-humans randomized clinical study.
Effector T-cell trafficking between the leptomeninges and the cerebrospinal fluid.

Pages